Fig. 1

Pulmonary function tests for Case 1 (A) and Case 2 (B). The solid line shows forced vital capacity and the dashed line shows forced expiratory volume (1 s) for both patients. The striped arrow in A represents the treatment-initiation of Dupilumab 300 mg SC. The open arrow in B represents the approximate time patient elected to discontinue treatment, filled arrow represents when treatment was restarted with budesonide/formoterol 160 mcg/4.5 mcg aerosol, the pixelated arrow represents the increase in Omalizumab updosing to 375 mg, the striped arrow represents the treatment-initiation of Dupilumab 300 mg SC in addition to Omalizumab